Written by : Dr. Aishwarya Sarthe
January 17, 2025
The funding will support the final stages of clinical trials, CDSCO approvals, research and development, patent filings, and team expansion.
CURO Biosciences, operating under ErlySign, has secured INR 16 Cr in pre-Series A funding.
The investment, led by Ashish Kacholia and facilitated by private equity advisory firm DerivativeSaint, aims to advance the development of a saliva-based test kit capable of detecting oral precancerous conditions.
The funding will support the final stages of clinical trials, CDSCO approvals, research and development, patent filings, and team expansion.
ErlySign’s test kit offers a simple, non-invasive solution to identify oral cancer risks within 15 minutes, addressing the challenges of existing diagnostic methods.
Shubhendra Singh Thakur, CEO and Founder of ErlySign, said, “Our initial studies revealed exceptional results, achieving 100 percent specificity and 98.04 percent sensitivity. The product, now in the final stages of clinical trials across multiple HCG sites, promises to be a game-changer. Beyond early detection, it will be a critical screening tool to eliminate unnecessary biopsies and invasive procedures.”
The saliva-based test kit is positioned as a cost-effective and efficient alternative to traditional diagnostic methods, which are often invasive, time-consuming, and expensive.
Clinical trials are being conducted to validate its efficacy before obtaining regulatory approvals.
The funding will also enable ErlySign to explore advanced diagnostic methods, including CRISPR miRNA-based testing technology. This approach could detect multiple cancer types using a single saliva sample within 15–20 minutes.
“The potential to use a non-invasive test for multiple cancers can significantly enhance accessibility and accuracy in early cancer detection,” Thakur added.
CURO Biosciences’ efforts align with the growing global diagnostics market, projected to reach $250 billion by 2030 and highlight the importance of early detection in improving survival rates.
With its focus on innovation and accessibility, ErlySign is poised to contribute significantly to healthcare advancements, particularly in oral cancer diagnostics.